RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has expanded its advisory relationships through the organization of an Infectious Disease Clinical Advisory Board (CAB). PolyMedix will engage the CAB members to actively collaborate on the clinical development of its novel defensin-mimetic antibiotic, PMX-30063 and other antimicrobial compounds. Members of the CAB are distinguished scientists and clinicians that will provide guidance to PolyMedix in their respective areas of expertise.
